ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
23/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseARQT / S&P 11.29% / 15.20% |
WinARQT / S&P 78.05% / 15.00% |
LoseARQT / S&P -128.38% / 50.40% |
| 2026-Q11/3 |
LoseARQT / S&P -18.87% / -4.33% |
WinARQT / S&P 98.08% / 11.30% |
LoseARQT / S&P -97.09% / 27.70% |
| 2025-Q42/3 |
WinARQT / S&P 54.06% / 2.65% |
WinARQT / S&P 123.41% / 9.00% |
LoseARQT / S&P -87.83% / 13.40% |
| 2025-Q32/3 |
WinARQT / S&P 34.45% / 8.12% |
WinARQT / S&P 183.56% / 4.61% |
LoseARQT / S&P -78.92% / 13.45% |
| 2025-Q21/3 |
LoseARQT / S&P -10.36% / 10.94% |
WinARQT / S&P 250.33% / 4.83% |
LoseARQT / S&P -64.08% / 10.63% |
| 2025-Q12/3 |
WinARQT / S&P 12.28% / -4.27% |
WinARQT / S&P 335.28% / 4.98% |
LoseARQT / S&P -63.21% / 10.57% |
| 2024-Q42/3 |
WinARQT / S&P 49.78% / 2.41% |
WinARQT / S&P 470.62% / 5.25% |
LoseARQT / S&P -69.66% / 6.15% |
| 2024-Q31/3 |
LoseARQT / S&P 0.00% / 5.89% |
WinARQT / S&P 494.53% / 5.89% |
LoseARQT / S&P -61.75% / 6.11% |
| 2024-Q21/3 |
LoseARQT / S&P -6.16% / 4.28% |
WinARQT / S&P 559.09% / 5.38% |
LoseARQT / S&P -62.55% / 5.12% |
| 2024-Q12/3 |
WinARQT / S&P 206.81% / 10.56% |
WinARQT / S&P 641.83% / 5.71% |
LoseARQT / S&P -50.44% / 5.59% |
| 2023-Q41/3 |
LoseARQT / S&P -39.17% / 11.69% |
WinARQT / S&P 691.81% / 6.81% |
LoseARQT / S&P -32.44% / 7.78% |
| 2023-Q31/3 |
LoseARQT / S&P -44.28% / -3.27% |
WinARQT / S&P 2468.41% / 7.52% |
LoseARQT / S&P -26.44% / -5.03% |
| 2023-Q21/3 |
LoseARQT / S&P -13.36% / 8.74% |
LoseARQT / S&P ARQT unavailable / 9.50% |
WinARQT / S&P 6.80% / -8.57% |
| 2023-Q11/3 |
LoseARQT / S&P -25.68% / 7.50% |
LoseARQT / S&P ARQT unavailable / 10.77% |
WinARQT / S&P 20.73% / -15.69% |
| 2022-Q41/3 |
LoseARQT / S&P -22.55% / 7.56% |
LoseARQT / S&P ARQT unavailable / 11.88% |
WinARQT / S&P 34.53% / -17.99% |
| 2022-Q31/3 |
LoseARQT / S&P -10.32% / -4.88% |
LoseARQT / S&P ARQT unavailable / 13.47% |
WinARQT / S&P 69.54% / -1.41% |
| 2022-Q22/3 |
WinARQT / S&P 10.64% / -16.10% |
LoseARQT / S&P ARQT unavailable / 13.71% |
WinARQT / S&P 53.73% / 11.04% |
| 2022-Q10/3 |
LoseARQT / S&P -7.14% / -4.60% |
LoseARQT / S&P ARQT unavailable / 15.97% |
LoseARQT / S&P 35.65% / 42.23% |
| 2021-Q40/3 |
LoseARQT / S&P -13.19% / 11.03% |
LoseARQT / S&P ARQT unavailable / 15.00% |
LoseARQT / S&P ARQT unavailable / 96.40% |
| 2021-Q30/3 |
LoseARQT / S&P -12.46% / 0.58% |
LoseARQT / S&P ARQT unavailable / 10.77% |
LoseARQT / S&P ARQT unavailable / 69.42% |
| 2021-Q20/3 |
LoseARQT / S&P -5.67% / 8.55% |
LoseARQT / S&P ARQT unavailable / 6.58% |
LoseARQT / S&P ARQT unavailable / 51.81% |
| 2021-Q10/3 |
LoseARQT / S&P 2.84% / 6.17% |
LoseARQT / S&P ARQT unavailable / -1.06% |
LoseARQT / S&P ARQT unavailable / 7.39% |
| 2020-Q40/3 |
LoseARQT / S&P -3.99% / 12.15% |
LoseARQT / S&P ARQT unavailable / -3.72% |
LoseARQT / S&P ARQT unavailable / -33.42% |
| 2020-Q30/3 |
LoseARQT / S&P -3.11% / 8.93% |
LoseARQT / S&P ARQT unavailable / -2.04% |
LoseARQT / S&P ARQT unavailable / -27.10% |
| 2020-Q20/3 |
LoseARQT / S&P 1.48% / 20.54% |
LoseARQT / S&P ARQT unavailable / -0.46% |
LoseARQT / S&P ARQT unavailable / -27.11% |
| 2020-Q10/3 |
LoseARQT / S&P ARQT unavailable / -19.60% |
LoseARQT / S&P ARQT unavailable / 3.47% |
LoseARQT / S&P ARQT unavailable / -14.75% |
| 2019-Q40/3 |
LoseARQT / S&P ARQT unavailable / 9.07% |
LoseARQT / S&P ARQT unavailable / 5.36% |
LoseARQT / S&P ARQT unavailable / 2.99% |
| 2019-Q30/3 |
LoseARQT / S&P ARQT unavailable / 1.70% |
LoseARQT / S&P ARQT unavailable / 5.02% |
LoseARQT / S&P ARQT unavailable / 0.21% |
| 2019-Q20/3 |
LoseARQT / S&P ARQT unavailable / 4.30% |
LoseARQT / S&P ARQT unavailable / 6.64% |
LoseARQT / S&P ARQT unavailable / 8.65% |
| 2019-Q10/3 |
LoseARQT / S&P ARQT unavailable / 13.65% |
LoseARQT / S&P ARQT unavailable / 8.12% |
LoseARQT / S&P ARQT unavailable / 14.29% |
| 2018-Q40/3 |
LoseARQT / S&P ARQT unavailable / -13.52% |
LoseARQT / S&P ARQT unavailable / 9.05% |
LoseARQT / S&P ARQT unavailable / 18.23% |
| 2018-Q30/3 |
LoseARQT / S&P ARQT unavailable / 7.71% |
LoseARQT / S&P ARQT unavailable / 10.21% |
LoseARQT / S&P ARQT unavailable / 19.06% |
| 2018-Q20/3 |
LoseARQT / S&P ARQT unavailable / 3.43% |
LoseARQT / S&P ARQT unavailable / 9.03% |
LoseARQT / S&P ARQT unavailable / 14.46% |
| 2018-Q10/3 |
LoseARQT / S&P ARQT unavailable / -0.76% |
LoseARQT / S&P ARQT unavailable / 7.68% |
LoseARQT / S&P ARQT unavailable / 12.46% |
| 2017-Q40/3 |
LoseARQT / S&P ARQT unavailable / 6.64% |
LoseARQT / S&P ARQT unavailable / 7.03% |
LoseARQT / S&P ARQT unavailable / 13.82% |
| 2017-Q30/3 |
LoseARQT / S&P ARQT unavailable / 4.48% |
LoseARQT / S&P ARQT unavailable / 5.68% |
LoseARQT / S&P ARQT unavailable / 17.57% |
| 2017-Q20/3 |
LoseARQT / S&P ARQT unavailable / 3.09% |
LoseARQT / S&P ARQT unavailable / 4.83% |
LoseARQT / S&P ARQT unavailable / 17.74% |
| 2017-Q10/3 |
LoseARQT / S&P ARQT unavailable / 6.07% |
LoseARQT / S&P ARQT unavailable / 3.67% |
LoseARQT / S&P ARQT unavailable / 13.32% |
| 2016-Q40/3 |
LoseARQT / S&P ARQT unavailable / 3.82% |
LoseARQT / S&P ARQT unavailable / 2.09% |
LoseARQT / S&P ARQT unavailable / 7.05% |
| 2016-Q30/3 |
LoseARQT / S&P ARQT unavailable / 3.85% |
LoseARQT / S&P ARQT unavailable / 0.20% |
LoseARQT / S&P ARQT unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ARQT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 60.24% | 20.78% |
| Annualized return | 60.24% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ARQT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 16.93% | 83.14% |
| Annualized return | 3.18% | 12.86% |
10Y · 2020-01-31 to 2026-08-27
| Metric | ARQT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 14.08% | 319.30% |
| Annualized return | 1.33% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |